MedTrace Logo

Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)

NCT05904054 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-04-30

No results posted yet for this study

Summary

This is an open-labeled, no placebo, Phase IIa clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of one booster vaccine dose of SARS-CoV-2 DNA Vaccine (ICCOV) in adults aged 18 to 75 years who have received two to four dosese of COVID-19 vaccine.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 DNA Vaccine (ICCOV)

The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • Immuno Cure 3 Limited

    lead INDUSTRY

Principal Investigators

  • Fan-ngai, Ivan Hung, Dr. · The University of Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2023-12-31
Completion
2024-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904054 on ClinicalTrials.gov